Adiponectin: A New Independent Predictor of Liver Steatosis and Response to IFN-α Treatment in Chronic Hepatitis C

• DOI: 10.1111/j.1572-0241.2007.01729.x
• Publication Date: 2008-03-13T15:35:11Z
• Authors: Theodoros A. Zogr...; Christos Liaskos; Eirini I. Rigopoulou; Elias Togousidis; Kostantinos Makar...; Anastasios Germenis; George N. Dalekos
• Keywords: Steatosis; Hepatitis C

OBJECTIVES To compare serum adiponectin and tumor necrosis factor (TNF)-α among patients with viral liver diseases; to investigate associations of TNF-α histological or characteristics chronic hepatitis C (CHC); alterations during interferon (IFN)-α treatment; assess the relationship between response rates treatment. METHODS Adiponectin (μg/mL) (pg/mL) determinations by enzyme-linked immunosorbent assay (ELISA) in serial samples (before, middle, end, 6 months after end treatment) from 83 CHC 59 B (CHB) patients. Forty-three blood donors served as healthy controls. Patients were treated IFN-α (4.5 MU/t.i.w.) for 12 CHB cases, (3 plus ribavirin 6–12 according virus (HCV) genotype cases. RESULTS After adjustment gender body mass index (BMI), HCV 3 overweight (BMI > 25 kg/m2) had significantly lower (7.3 ± 2.7) at baseline compared non-3 (P < 0.05). Lower (HCV 3, P= 0.02 1, 0.025) higher (P= identified independent predictors steatosis was also an predictor no virological treatment (odds ratio [OR] 0.76, 95% confidence interval [CI] 0.66–0.87, P 0.001). At therapy, only (10.4 6.3) its levels before (8.7 4.7, CONCLUSIONS This study suggests that may directly affect adiponectin. is further supported significant increase Serum appears be achievement end-of-treatment response, while steatosis.